Status:
UNKNOWN
A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours
Lead Sponsor:
National University Hospital, Singapore
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
21+ years
Brief Summary
OPB-51602 is a novel oral small molecule STAT3 inhibitor developed by Otsuka Pharmaceutical Company, Ltd, and is currently undergoing clinical investigation at the National University Health System (N...
Eligibility Criteria
Inclusion
- Advanced Solid Tumor
Exclusion
- Non advanced solid tumor
Key Trial Info
Start Date :
May 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2015
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01867073
Start Date
May 1 2011
End Date
May 1 2015
Last Update
June 3 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore